151 related articles for article (PubMed ID: 8295510)
1. Differentiation of hepatomas from nonhepatomatous masses: use of MnDPDP-enhanced MR images.
Liou J; Lee JK; Borrello JA; Brown JJ
Magn Reson Imaging; 1994; 12(1):71-9. PubMed ID: 8295510
[TBL] [Abstract][Full Text] [Related]
2. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
4. MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool.
Helmberger TK; Laubenberger J; Rummeny E; Jung G; Sievers K; Döhring W; Meurer K; Reiser MF
Eur Radiol; 2002 Jan; 12(1):62-70. PubMed ID: 11868075
[TBL] [Abstract][Full Text] [Related]
5. Technical report: lymph node enhancement at MRI with MnDPDP in primary hepatic carcinoma.
Burkill GJ; Mannion EM; Healy JC
Clin Radiol; 2001 Jan; 56(1):67-71. PubMed ID: 11162701
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 mumol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique.
Padovani B; Lecesne R; Raffaelli C; Chevallier P; Drouillard J; Bruneton JN; Lambrechts M; Gordon P
Eur J Radiol; 1996 Nov; 23(3):205-11. PubMed ID: 9003926
[TBL] [Abstract][Full Text] [Related]
7. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of biphasic spiral CT and MnDPDP-enhanced MRI in the detection and characterization of liver lesions].
Grimm J; Müller-Hülsbeck S; Blume J; Biederer J; Heller M
Rofo; 2001 Mar; 173(3):266-72. PubMed ID: 11293872
[TBL] [Abstract][Full Text] [Related]
9. MnDPDP as a negative hepatic contrast agent: evaluation of STIR imaging compared with T1-weighted SE and GE techniques.
Halavaara JT; Lamminen AE
J Comput Assist Tomogr; 1997; 21(1):94-9. PubMed ID: 9022776
[TBL] [Abstract][Full Text] [Related]
10. Small (Kim KW; Kim AY; Kim TK; Park SH; Kim HJ; Lee YK; Park MS; Ha HK; Kim PN; Kim JC; Lee MG
AJR Am J Roentgenol; 2004 May; 182(5):1233-40. PubMed ID: 15100125
[TBL] [Abstract][Full Text] [Related]
11. MnDPDP enhanced magnetic resonance imaging of focal liver lesions.
King LJ; Burkill GJ; Scurr ED; Vlavianos P; Murray-Lyons I; Healy JC
Clin Radiol; 2002 Dec; 57(12):1047-57. PubMed ID: 12475527
[TBL] [Abstract][Full Text] [Related]
12. MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis.
Bartolozzi C; Donati F; Cioni D; Crocetti L; Lencioni R
Eur Radiol; 2000; 10(11):1697-702. PubMed ID: 11097390
[TBL] [Abstract][Full Text] [Related]
13. Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients.
Hamm B; Vogl TJ; Branding G; Schnell B; Taupitz M; Wolf KJ; Lissner J
Radiology; 1992 Jan; 182(1):167-74. PubMed ID: 1309218
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging.
Rofsky NM; Weinreb JC; Bernardino ME; Young SW; Lee JK; Noz ME
Radiology; 1993 Jul; 188(1):53-9. PubMed ID: 8390072
[TBL] [Abstract][Full Text] [Related]
15. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics.
Kim JH; Kim MJ; Park YN; Lee JT; Kim BR; Chung JB; Choi JS; Kim KS; Kim KW
Clin Radiol; 2008 Nov; 63(11):1195-204. PubMed ID: 18929037
[TBL] [Abstract][Full Text] [Related]
16. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
[TBL] [Abstract][Full Text] [Related]
17. Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.
Eser G; Karabacakoglu A; Karakose S; Eser C; Kayacetin E
World J Gastroenterol; 2006 Mar; 12(10):1603-6. PubMed ID: 16570354
[TBL] [Abstract][Full Text] [Related]
18. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study of four GRE sequences in MnDPDP-enhanced magnetic resonance imaging for primary hepatocellular carcinoma].
Guo T; Zhang XL; Chang RM; Zhang YZ
Di Yi Jun Yi Da Xue Xue Bao; 2003 Sep; 23(9):946-8. PubMed ID: 13129729
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging.
Elizondo G; Fretz CJ; Stark DD; Rocklage SM; Quay SC; Worah D; Tsang YM; Chen MC; Ferrucci JT
Radiology; 1991 Jan; 178(1):73-8. PubMed ID: 1898538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
